Recipharm expands Swedish facility; FDA warns Chinese OTC maker; DSM, Indoco ink pact;

> Sweden's Recipharm will expand capacity of its analytical services and stability studies at its facility in Solna, Sweden. Release

> The FDA has warned Shanghai Huhui Daily Use Chemical Products that its products may be refused entry into the U.S. until it fixes a host of problems inspectors found at its manufacturing plant in Shanghai. Warning Letter

> India-based packaging company ACG Worldwide is plunking down about $71 million in the phased construction of a new manufacturing plant at Pithampur, Indore, India. Item

> DSM Pharmaceuticals has struck a deal with Indian API maker Indoco Remedies to sell 8 of its active pharmaceutical ingredients. Item

And Finally... With the patent cliff ending for branded drugmakers, the fiscal precipice now looms for generics makers. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.